Remikiren
![]() | |
Systematic (IUPAC) name | |
---|---|
(2S)-2-[(2R)-2-benzyl-3-(2-methylpropane-2-sulfonyl)propanamido]-N-[(2R,3S,4R)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]-3-(1H-imidazol-4-yl)propanamide | |
Clinical data | |
Legal status |
|
Identifiers | |
CAS Number |
126222-34-2 ![]() |
ATC code | C09XA01 (WHO) |
PubChem | CID 6324659 |
DrugBank |
DB00212 ![]() |
ChemSpider |
4884377 ![]() |
UNII |
LC7FBL96A4 ![]() |
KEGG |
D09038 ![]() |
ChEMBL |
CHEMBL31601 ![]() |
Chemical data | |
Formula | C33H50N4O6S |
Molar mass | 630.839 g/mol |
| |
| |
(verify) |
Remikiren is a renin inhibitor under development for the treatment of hypertension (high blood pressure). It was first developed by Hoffmann–La Roche in 1996.[1]
References
- ↑ Richter WF, Whitby BR, Chou RC (1996). "Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals". Xenobiotica 26 (3): 243–54. doi:10.3109/00498259609046705. PMID 8730917.
|
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.